Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors (TKIs). The study published today in Cancer Cell.
https://www.lifetechnology.com/blogs/life-technology-medical-news/lung-cancer-study-finds-new-target-for-treatment-resistance-after-egfr-inhibitors
Buy SuperforceX™
